Similar articles

• The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

  Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. Johannes CB, et al. Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12. doi: 10.1002/pds.1356. Pharmacoepidemiol Drug Saf. 2007. PMID: 17245800
• The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

  Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators. Comaschi M, et al. Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):373-9. doi: 10.1016/j.numecd.2007.04.003. Epub 2007 Oct 24. Nutr Metab Cardiovasc Dis. 2008. PMID: 17919894 Clinical Trial.
• The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

  Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. Pantalone KM, et al. Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5. Acta Diabetol. 2009. PMID: 19194648
• [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].

  Nauck MA, Matthaei S. Nauck MA, et al. Dtsch Med Wochenschr. 2005 Apr 29;130(17):1091-6. doi: 10.1055/s-2005-866793. Dtsch Med Wochenschr. 2005. PMID: 15841424 Review. German. No abstract available.
• Treating type 2 diabetes: targeting the many causative factors.

  Sutherland JE, Hoehns JD. Sutherland JE, et al. J Fam Pract. 2004 May;53(5):376-88. J Fam Pract. 2004. PMID: 15125823 Review. No abstract available.